The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC
Official Title: A Phase II Trial to Assess the Efficacy and Safety Profile of Pembrolizumab in Patients With Performance Status 2 With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Study ID: NCT03813836
Brief Summary: A single-arm phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status of 2 with recurrent or metastatic squamous cell carcinoma of the head and neck. Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Aberdeen Royal Infirmary (NHS Grampian), Aberdeen, , United Kingdom
Bristol Haematology and Oncology Centre (University Hospital Bristol NHS Foundation Trust), Bristol, , United Kingdom
Western General Hospital (NHS Lothian), Edinburgh, , United Kingdom
East Suffolk and North Essex NHS Foundation Trust, Ipswich, , United Kingdom
Guy's and St Thomas' NHS Foundation Trust, London, , United Kingdom
University College London Hospital, London, , United Kingdom
The Christie NHS Foundation Trust, Manchester, , United Kingdom
East and North Hertfordshire NHS Trust, Northwood, , United Kingdom
Queens Hospital (Barking, Havering and Redbridge University Hospitals NHS Trust), Romford, , United Kingdom
Musgrove Park Hospital (Somerset NHS Foundation Trust), Taunton, , United Kingdom
Royal Cornwall Hospital Trust, Truro, , United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, , United Kingdom
Name: Martin Forster, FRCP PhD
Affiliation: University College, London
Role: PRINCIPAL_INVESTIGATOR